Coronary heart disease (CHD) has. Clearfield The National Cholesterol Education Program Adult Treatment Panel III guidelines
|
|
- Avis Short
- 6 years ago
- Views:
Transcription
1 the osteopathic physician. The treatment approach involves therapeutic lifestyle changes with diet, exercise, and weight loss. It requires regular, careful monitoring of serum cholesterol levels. The new ATP III guidelines expand greatly the total number of patients who are eligible for treatment of hypercholesterolemia. Definite goals for LDL-C are defined for patients with coronary heart disease and patients at risk for subsequent clinical events. Many, if not most of these patients, will not be able to achieve their target LDL-C level without pharmacologic therapy. The ATP III evidence-based guidelines have defined the standard. It is our responsibility and unique opportunity to fulfill these expectations through thoughtful clinical practice. We might consider this supplement to represent a tool to help us accomplish this task. References 1. Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285: The American Heart Association 2002 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2001; pp Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160: Stafford RS, Blumenthal D, Pasternak RC. Variations in cholesterol management practices of US physicians. J Am Coll Cardiol. 1997;29: Bramlett DA, King H, Young L, Witt JR, Stoukides CA, Kaul AF. Management of hypercholesterolemia: practice patterns for primary care providers and cardiologists. Am J Cardiol. 1997;80:39H-44H. Dr Rogers, a practicing cardiologist, is a clinical professor in the Department of Internal Medicine at the Michigan State University College of Osteopathic Medicine in East Lansing. fjrogers@aol.com This educational program was developed from information presented during a scientific symposium conducted on October 11, 2002, in Las Vegas, Nevada, at the 2002 Annual Convention and Scientific Seminar of the American Osteopathic Association. Coronary heart disease (CHD) remains the leading cause of death in the United States with more than 40% of all deaths each year directly attributed to the disease. Current evidence suggests that early identification and aggressive modification of risk factors offer the most promising approach to reducing the burden of CHD. Dyslipidemia has been identified as the primary risk factor leading to the development of CHD. It is estimated that nearly 65 million Americans require some form of lipid-modification therapy. The National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) set of guidelines released in May 2001 provides physicians with evidence-based recommendations on the classification, diagnosis, and treatment of lipid disorders. New features of the guidelines include a scoring system for calculating CHD risk, as well as the identification of CHD risk equivalents, lower treatment target goals, and an emphasis on conditions conferring a higher risk for CHD, such as the metabolic syndrome. The ATP III emphasis on risk assessment substantially increases the number of patients considered at risk for CHD and will expand the number eligible for lifestyle and drug interventions. This article highlights the new recommendations and reviews the impact of ATP III on osteopathic physicians. (Key words: atherosclerosis, cholesterol, coronary heart disease, dyslipidemia, low-density lipoprotein cholesterol [LDL-C]) Coronary heart disease (CHD) has persisted as the single leading cause of death among Americans. According to the American Heart Association, 1 more than 1.1 million new or recurrent myocardial infarctions occurred in 2000 and more than 500,000 Americans died of CHD-related causes. Coronary heart disease also places a significant financial burden on the US economy with The National Cholesterol Education Program Adult Treatment Panel III guidelines Michael B. Clearfield, DO direct and indirect costs of the disease estimated to be nearly $330 billion in Dyslipidemia is recognized as a major modifiable risk factor for the development and progression of CHD. Numerous clinical trials have demonstrated that CHD-related morbidity and mortality is reduced after aggressive intervention that includes both lifestyle Dr Clearfield is a professor of medicine and associate dean for clinical research at the University of North Texas Health Science Center at Fort Worth/Texas College of Osteopathic Medicine. Dr Clearfield represented the American Osteopatic Association, a member organization of the National Cholesterol Education Program Coordinating Committee, which approved the Third Report of the National Cholesterol Education Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Dr Clearfield is a member of the speakers bureau of AstraZeneca, Merck & Co, Pfizer Inc, and Sankyo Pharma Inc, and he has received grant/research support from AstraZeneca and Pfizer Inc. Correspondence to Michael B. Clearfield, DO, Associate Dean for Clinical Research, Office of the Dean, Texas College of Osteopathic Medicine, University of North Texas Health Science Center at Fort Worth, 855 Montgomery St, Fort Worth, TX mclearfi@hsc.unt.edu JAOA Supplement 1 Vol 103 No 1 January 2003 S1
2 modifications and pharmacologic therapy. 2-5 In May 2001, the Adult Treatment Panel (ATP) of the National Cholesterol Education Program (NCEP) issued its third set of guidelines (NCEP ATP III) for the identification and management of dyslipidemia. 6 Building on ATP I (1988) and ATP II (1993), ATP III pays increased attention to the identification and quantification of risk factors for CHD and therefore vastly expands the number of Americans eligible for lipid-lowering therapy. With these changes, ATP III presents a challenge to physicians and the healthcare system to identify at-risk patients, implement effective therapy, and ensure that patients meet target goals (Figure 1). Osteopathic physicians, many of whom focus on primary care with an emphasis on treating the entire patient, are in the vanguard for the reduction of CHD risk. Therefore, osteopathic physicians are uniquely positioned to have an impact on the implementation of the new guidelines. New features of the ATP III guidelines Consistent with previous editions, the new ATP guidelines provide an evidence-based approach for the detection and treatment of lipid disorders. Adult Treatment Panel III follows ATP II by continuing to focus on reduction of lowdensity lipoprotein cholesterol (LDL-C) as the primary goal of therapy and advocates that the intensity of therapy be adjusted to the degree of risk. The ATP III set of guidelines also reiterates the importance of lifestyle changes such as weight loss, dietary modifications, and increased physical activity in reducing CHD risk (Figure 1). New features of the guidelines include the use of a risk assessment tool based on data derived from the Framingham Heart Study, 7 the identification of diabetes (with or without clinically evident CHD) as a CHD risk equivalent, more aggressive lipid target levels, and the recognition that patients with the metabolic syndrome should be provided intensified lipid-modification therapy (Figure 1). Adult Treatment Panel III places patients into one of three categories of Checklist Challenges Identify patients at risk for CHD Implement effective therapy Ensure that patients meet target goals Emphasis Risk assessment Reduction of low-density lipoprotein cholesterol (LDL-C) as primary goal of therapy Adjustment of intensity of therapy to degree of risk Importance of lifestyle changes to include: weight loss dietary modifications increased physical activity New features Use of a risk assessment tool based on data derived from the Framingham Heart Study Identification of diabetes as a coronary heart disease (CHD) risk equivalent More aggressive lipid target goals Intensified lipid-modification therapy for patients with the metabolic syndrome Raising target for high-density lipoprotein cholesterol level (to 40 mg/dl) Lowering target for triglyceride concentration (to 200 mg/dl) Strategies for promoting adherence to treatment regimens Figure 1. Challenges, emphasis, and new features of the Adult Treatment Panel III guidelines. CHD risk (high, moderate, low) and identifies specific LDL-C treatment goals for each (Figure 2). The LDL-C target levels for patients with CHD and CHD risk equivalents (highest risk) are now less than 100 mg/dl. For patients with two or more risk factors (moderate risk), the target level is less than 130 mg/dl, and for patients with zero or one risk factor (low risk), the goal is less than 160 mg/dl. Adult Treatment Panel III also recognizes the role high-density lipoprotein cholesterol (HDL-C) and triglycerides play in modifying CHD risk and therefore raised the target level for HDL-C from less than 35 mg/dl to less than 40 mg/dl and lowered target goals for triglycerides to less than or equal to 200 mg/dl. Further, ATP III recognizes that the heightened emphasis on risk assessment, the inclusion of CHD risk equivalents, and the more aggressive treatment goals will significantly increase the number of patients eligible for therapy and challenge physicians and the healthcare delivery system to implement the guidelines. Therefore, ATP III also presents strategies for promoting adherence totherapeutic lifestyle changes (TLC) and drug therapy. Assessment of risk for coronary heart disease The Framingham risk scoring system incorporated into ATP III quantifies the 10-year risk for a coronary event. Point scores are calculated according to the presence of five major CHD risk factors (age and gender, total cholesterol, systolic blood pressure, HDL-C level, and smoking status), with each risk factor worth a certain number of points. When added together, the sum yields an estimate of the risk for having a coronary event in 10 years. A properly conducted assessment places patients into one of the three risk categories and forms the basis for all subsequent treatment decisions. Patients with documented CHD and CHD risk equivalents are automatically placed in the highest risk category. The CHD risk equivalents carry a risk for a major coronary event equal to that of established CHD and include diabetes, peripheral vascular disease, symptomatic carotid artery disease, and abdominal aortic aneurysm. The new set of guidelines places patients with these conditions in the same risk category as those with clinically evident CHD (eg, 20% 10-year risk of CHD). The LDL-C treatment goal for patients in this high-risk category is less than 100 mg/dl. In patients without documented CHD or CHD equivalents, assessment of CHD risk using the Framingham risk quantification system is essential to determine the most appropriate course of therapy. Patients with two or more major risk factors are considered to be at a moderately increased risk for CHD, with a 10-year risk of less than 20%. Therapy for the patients in this category should be S2 JAOA Supplement 1 Vol 103 No 1 January 2003
3 Risk stratification High risk of coronary heart disease (CHD) (documented CHD or CHD risk equivalent) Moderate (two or more risk factors) Low (zero to one risk factor) Adult Treatment Panel III sufficient to enable them to achieve an LDL-C target level of less than 130 mg/dl. Patients at the lowest risk are those with one or fewer major risk factors. In all but rare cases, these individuals have a 10-year risk of less than 10%. The target LDL-C level in this group of patients is less than 160 mg/dl. Current treatment trends With the increased emphasis on risk assessment and aggressive new treatment goals, it is estimated that the number of patients eligible for CHD risk reduction through lipid-modification therapy in the United States is currently at 65 million. The type and extent of therapy is dependent on the patient s CHD risk. Two primary modalities advocated by ATP III for lowering LDL-C, and therefore CHD risk, are ATP TLC and drug therapy. Treatment goal level (low-density lipoprotein cholesterol) 100 mg/dl 130 mg/dl 160 mg/dl Figure 2. Low-density lipoprotein cholesterol goals according to risk factor stratification. (Source: Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Full Report. Available at: nih.gov/guidelines/cholesterol/atp3_rpt.htm. Accessed December 2, 2002.) Therapeutic lifestyle changes First-line therapy for all patients is TLC and may be substantial enough in groups at lower risk to reach their LDL-C goals. Components of TLC that have demonstrated effectiveness in lowering LDL-C include eating a healthy diet, regular physical activity, smoking cessation, and weight loss. Dietary changes should include a reduction of saturated fats to less than 7% of total calories, reduction of intake of dietary cholesterol to less than 200 mg/d, addition of plant sterols and stanols at a level of 2 g/d (commercially available in special margarines), and incorporating viscous fiber into the diet at a level of 10 g/d to 25 g/d. Weight reduction can reduce LDL-C levels and ameliorate the risk factors associated with the metabolic syndrome by improving insulin sensitivity and serum glucose uptake. Physical activity raises HDL-C levels and decreases the concentration of very low-density lipoprotein cholesterol and triglycerides. Smoking cessation also results in a reduction of CHD risk. Pharmacologic therapy Although ATP III emphasizes the importance of nonpharmacologic therapy, it recognizes limitations of such therapy and encourages the addition of drug therapy if TLC fails to move a patient to goal after 3 months. High-risk patients will most likely require drug therapy along with TLC from the onset of treatment. As stated earlier, treatment goals and lipid thresholds for initiating drug therapy are based on the patient s degree of risk. For patients with the highest risk for coronary events, the LDL-C threshold for initiation of therapy is greater than or equal to 130 mg/dl (after a 3-month trial of TLC) and the goal is less than 100 mg/dl. For patients with LDL-C between 100 mg/dl and 129 mg/dl, drug therapy is optional and physicians are encouraged to use their professional clinical judgment to determine the nature of therapy required to reduce CHD risk. For patients with moderate risk without definite CHD or CHD risk equivalents but with more than two major risk factors and a 10-year risk of 10% to 20%, the threshold is greater than or equal to 130 mg/dl and the target is also less than 130 mg/dl. For patients at moderate risk but with a 10-year risk of less than 10%, the threshold for LDL-C is greater than or equal to 160 mg/dl and the target is less than 130 mg/dl. For patients without CHD and with zero to one major risk factor, drug treatment should be considered if the LDL-C cholesterol level is greater than or equal to 190 mg/dl after 3 months of TLC, with a goal of greater than or equal to 160 mg/dl. In all cases of drug therapy, TLC should continue to be maintained and reinforced. Currently available lipid-modifying drugs Four classes of lipid-modifying drugs are currently available in prescription form, including bile acid sequestrants, nicotinic acids, fibric acid derivatives, JAOA Supplement 1 Vol 103 No 1 January 2003 S3
4 and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins). Statins, the most widely used lipid-modifying agent, decrease LDL-C by inhibiting cholesterol synthesis and reduce LDL-C by 25% to 50% in a dosedependent manner. The currently available statins are differentiated by the LDL-C lowering elicited at a given dose. Several large clinical outcomes trials have demonstrated that statin use reduces the incidence of CHD events, including myocardial infarction, coronary death, stroke, and total mortality. 2-5 Bile acid sequestrants are another commonly used agent. Bile acid sequestrants can be used as monotherapy when moderate reductions in LDL-C are required to achieve goal or as add-on therapy to statins, particularly in patients with severe dyslipidemia. A third class of agents is nicotinic acid, or niacin. Nicotinic acids provide a moderate LDL-C lowering action, but the primary utility of these agents is in combination with statins for patients who have elevated triglyceride concentrations or low HDL-C levels or both. Fibric acids, or fibrates, are a fourth class of lipid-modifying agents that possess minimal LDL-C reducing capacity, but these agents are useful in patients with combined forms of hyperlipidemia. Fibrates are especially effective in patients who have severe hypertriglyceridemia. Despite the efficacy of statins in modifying lipid levels and reducing coronary events, alternative agents are needed. Some patients are unable to tolerate statins, or they are not candidates for use of these agents because of either or both tolerability and safety concerns. In these cases, physicians and patients are forced to use bile acid sequestrants, niacin, fibrates, or other less common modes of therapy. These agents, however, vary in their effectiveness in reducing LDL-C levels owing to low efficacy of the agent or poor compliance due to undesired side effects. A promising new alternative mode of therapy was recently approved by the US Food and Drug Administration (FDA). Phase II data suggest that ezetimibe, the first selective inhibitor of intestinal cholesterol absorption, appears to have substantial potential for use as monotherapy in patients at low risk for CHD who require only a modest reduction in their LDL-C level or for those who do not tolerate statin therapy. 8 In addition, ezetimibe, when used in combination with a low-dose statin in patients at moderate to high risk for CHD, can elicit a reduction in LDL-C comparable to reductions seen at the highest statin doses. 9 Implementation of the ATP III guidelines The ATP III set of guidelines, with an emphasis on risk assessment and new treatment goals, presents an enormous challenge to physicians and the healthcare system in terms of implementation and patient compliance. Previous guideline adherence rates indicate that achieving the new goals will be difficult. The ATP II guidelines, although much less complex, were rarely followed in patients with CHD, let alone in patients with subclinical disease. Data from the Lipid Treatment Assessment Project (L-TAP) 10 demonstrated that only 18% of those with CHD achieved ATP II goals and that less than 40% of all patients on lipid-modification therapy receive sufficient lipid lowering to reduce CHD risk. Because overall adherence and goal achievement was low with previous guidelines, the challenges inherent in achieving ATP III goals are clear. The ATP III acknowledges that primary prevention of CHD offers the greatest opportunity for reducing the clinical and economic burden of CHD in the United States. The clinical approach to CHD prevention begins in the primary care office and requires an informed physician who does not focus solely on a specific symptom and who implements early risk screening that includes an assessment of the overall health of the patient. Because nearly 60% of all osteopathic physicians practice in primary care and account for more than 100 million primary care visits per year, they are uniquely positioned to influence the implementation of the ATP III guidelines. Thus, DOs can have a significant impact on the reduction of CHD risks in their patients. Osteopathic physicians also treat a large number of patients who have limited access to healthcare. Consequently, DOs must educate their patients about the importance of taking responsibility for their own health through the incorporation of healthy lifestyle habits. Comments The NCEP ATP III report updates the clinical guidelines for the detection and treatment of lipid disorders. Although the emphasis remains on reducing longterm CHD risk by lowering the LDL-C level, new features of the guidelines include a scoring system for calculating CHD risk as well as the identification of CHD risk equivalents. The ATP III emphasis on risk assessment will substantially increase the number of individuals considered to be at risk for CHD and will expand the number of patients who will be eligible for lifestyle and drug interventions. The new recommendations will significantly challenge physicians to screen and treat patients to more aggressive target lipid levels. Osteopathic physicians are uniquely positioned to implement the new guidelines and encourage patient compliance. References 1. American Heart Association Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2001: pp 4, 11, Scandinavian Simvastatin Survival Study Group. Randomised Trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998;97: Downs JR, Clearfield M, Weis S, Whitney F, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279: Sacks FM, Moyé LA, Davis BR, Cole TG, Rouleau JL, Nash DT, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation. 1998;97: Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treat- S4 JAOA Supplement 1 Vol 103 No 1 January 2003
5 ment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285: Wilson PW, D Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97: Bays H, Drehobl M, Rosenblatt S, Toth P, Dujovne C, Knopp R, et al. Low density lipoprotein cholesterol reduction by SCH (ezetimibe), a novel inhibitor of cholesterol absorption, in 234 hypercholesterolemic subjects: results of a dose-response study. Atherosclerosis. 2000;151:133. Abstract. 9. Davis HR, Watkins RW, Compton DS, Cook JA, Hoos L, Pula K, et al. The cholesterol absorption inhibitor SCH and lovastatin synergistically lower plasma cholesterol and inhibit the development of atherosclerosis. J Am Coll Cardiol. 2000;35(2 suppl):252a. Abstract. 10. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieveing low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160: Underidentification and undertreatment of dyslipidemia Michael B. Clearfield, DO Despite increased attention placed on the identification and treatment of dyslipidemia, this condition remains undiagnosed and untreated in a significant number of patients. The recently released National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) set of cholesterol management guidelines increases to more than 65 million the number of Americans eligible for lipid-modifying therapy. Recent data, however, suggest that even with the availability of multiple regimens with proven efficacy, as many as 50% of all patients do not have their cholesterol assessed and less than 45% receive lipid-modifying therapy. In addition, less than 25% of patients are treated to their NCEP target low-density lipoprotein cholesterol (LDL-C) level. Persistence with therapy is another challenge, as more than 70% of patients fail to maintain their therapy beyond 12 months. If a realistic attempt is to be made to reduce the risk of coronary heart disease (CHD) among Americans, diagnosis of dyslipidemia and treatment to therapeutic targets must be improved. This article discusses the underdiagnosis and undertreatment of lipid disorders and reviews the role of osteopathic physicians in strategies achieving ATP III LDL-C goals. (Key words: Adult Treatment Panel III [ATP III], compliance, cholesterol, dyslipidemia) Large numbers of patients have undiagnosed dyslipidemia, and those who do receive a diagnosis are often given inadequate therapy. The American Heart Association 1 estimates that more than 100 million adults in the United States have total cholesterol levels greater than 200 mg/dl and at least 40% of these individuals have cholesterol levels in excess of 240 mg/dl. The true number of dyslipidemic individuals in the United States may never be known because of the enormity of effort and magnitude of cost required for screening all at-risk individuals. Because more than 12.6 million Americans have coronary heart disease (CHD) and more than 500,000 deaths are attributed to this disease each year, physicians should be strongly encouraged to heed the advice of the National Cholesterol Education Pro- Dr Clearfield is a professor of medicine and associate dean for clinical research at the University of North Texas Health Science Center at Fort Worth/Texas College of Osteopathic Medicine. Dr Clearfield represented the American Osteopatic Association, a member organization of the National Cholesterol Education Program Coordinating Committee, which approved the Third Report of the National Cholesterol Education Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Dr Clearfield is a member of the speakers bureau of AstraZeneca, Merck & Co, Pfizer Inc, and Sankyo Pharma Inc, and he has received grant/research support from AstraZeneca and Pfizer Inc. Correspondence to Michael B. Clearfield, DO, Associate Dean for Clinical Research, Office of the Dean, Texas College of Osteopathic Medicine, University of North Texas Health Science Center at Fort Worth, 855 Montgomery St, Fort Worth, TX mclearfi@hsc.unt.edu Clearfield Underidentification and undertreatment of dyslipidemia JAOA Supplement 1 Vol 103 No 1 January 2003 S5
Nearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III
... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III Robert L. Talbert, PharmD Abstract Coronary heart disease (CHD) is a common, costly, and undertreated
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationThe new guidelines issued in PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice
... PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice Based on a presentation by Daniel J. Rader, MD Presentation Summary The guidelines recently released by the National Cholesterol
More informationNew Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines
Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular
More information... CPE/CNE QUIZ... CPE/CNE QUESTIONS
CPE/CNE QUESTIONS Continuing Pharmacy Education Accreditation The Virginia Council on Pharmaceutical Education is approved by the American Council on Pharmaceutical Education as a provider of continuing
More informationRECOGNITION OF THE METABOLIC SYNDROME
THE METABOLIC SYNDROME IN CLINICAL PRACTICE Michael H. Davidson, MD* ABSTRACT Patients with the metabolic syndrome remain at significantly elevated risk of morbidity and mortality associated with coronary
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationCoronary artery disease remains the leading
UNMET NEEDS IN THE TREATMENT OF ATHEROSCLEROSIS: WHY ARE WE NOT DONE YET? * Evan A. Stein, MD, PhD ABSTRACT Heart disease remains the leading cause of death in the United States. Despite advances in surgical,
More informationComparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients
Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Cardiology Department, Bangkok Metropolitan Medical College and Vajira Hospital, Bangkok, Thailand Abstract
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationB. Patient has not reached the percentage reduction goal with statin therapy
Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels
More informationTraditionally, clinicians and medical practitioners
MANAGING DYSLIPIDEMIA THROUGH THE PA PATIENT RELATIONSHIP * John R. White, Jr, PharmD, PA-C ABSTRACT Cardiovascular disease (CVD) is the leading cause of death in the Western world and in the United States.
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationOn May 2001, the Third Adult
THE RISK OF DIABETES: CAN WE IMPACT CHD THROUGH THE ATP III CHOLESTEROL GUIDELINES? * Based on a presentation given by Steven M. Haffner, MD, MPH ABSTRACT Diabetes has been recognized among diabetologists
More informationPharmaceutical Help to Control Cholesterol
Pharmaceutical Help to Control Cholesterol Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. Clinical Associate Professor, Univ. of Maryland This program has been brought to you by PharmCon
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More informationHistorically, the term control has been
MANAGEMENT OF DYSLIPIDEMIA: IMPLICATIONS OF THE ADULT TREATMENT PANEL (ATP) III RECOMMENDATIONS James M. McKenney, PharmD 1 ABSTRACT The emphasis in managing dyslipidemia should be given to achieving and
More informationThe American Diabetes Association estimates
DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular
More informationGUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES
GUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES Prepared by DCPNS Action Committee Dr. Lynne Harrigan Brenda Cook Peggy Dunbar Bev Harpell with the assistance
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationThreshold Level or Not for Low-Density Lipoprotein Cholesterol
... SYMPOSIA PROCEEDINGS... Threshold Level or Not for Low-Density Lipoprotein Cholesterol Based on a debate between Philip J. Barter, MD, PhD, FRACP, and Frank M. Sacks, MD Debate Summary As drugs, such
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationMedical evidence suggests that
COMBINATION THERAPY TO ACHIEVE LIPID GOALS David G. Robertson, MD* ABSTRACT Coronary heart disease (CHD) remains the leading cause of death in the United States despite recent advances in treatment and
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationPreventing Myocardial Infarction in the Young Adult in the First Place: How Do the National Cholesterol Education Panel III Guidelines Perform?
Journal of the American College of Cardiology Vol. 41, No. 9, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00187-6
More informationORIGINAL INVESTIGATION. The Lipid Treatment Assessment Project (L-TAP)
ORIGINAL INVESTIGATION The Lipid Treatment Assessment Project (L-TAP) A Multicenter Survey to Evaluate the Percentages of Dyslipidemic Patients Receiving Lipid-Lowering Therapy and Achieving Low-Density
More informationIn May 2001, the National Cholesterol. Effective Management of Patients With Dyslipidemia REPORT. Robert J. Lipsy, PharmD
REPORT Effective Management of Patients With Dyslipidemia Robert J. Lipsy, PharmD Abstract Coronary heart disease (CHD) is the leading cause of morbidity and mortality in the United States. A direct relationship
More informationTreating Lipids for Prevention of CAD in Women: Matching Therapy to Risk
TREATING LIPIDS FOR PREVENTION OF CAD IN WOMEN: MATCHING THERAPY TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationReducing low-density lipoprotein cholesterol treating to target and meeting new European goals
European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationDyslipidemia and HIV NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Dyslipidemia and HIV Heidi Crane, MD, MPH Madison Metabolic Clinic Associate Professor UW Department of Medicine Presentation prepared by: Heidi Crane, MD,
More informationSafety profile of atorvastatin-treated patients with low LDL-cholesterol levels
Atherosclerosis 149 (2000) 123 129 www.elsevier.com/locate/atherosclerosis Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels Rebecca G. Bakker-Arkema *, James W. Nawrocki,
More informationClinical Practice Guideline
Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)
More informationDisclosures. Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA. Learning Objectives. Atherogenesis. Acceptable Values
39 th National Conference on Pediatric Health Care Pediatric Dyslipidemia Casey Elkins, DNP, NP C, CLS, FNLA March 19-22, 2018 CHICAGO Disclosures Speakers Bureau Sanofi and Regeneron Learning Objectives
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationnicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck
Scottish Medicines Consortium Resubmission nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck New formulation 6 January 2006 The Scottish Medicines Consortium
More informationCLINICAL. Determinants of Compliance With Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population
Determinants of Compliance With Statin Therapy and Low-Density Lipoprotein Cholesterol Goal Attainment in a Managed Care Population Jennifer S. Schultz, PhD; John C. O Donnell, PhD; Ken L. McDonough, MD;
More informationInternational Journal of Research and Development in Pharmacy and Life Sciences. Research Article
International Journal of Research and Development in Pharmacy and Life Sciences Available online at http//www.ijrdpl.com February - March, 214, Vol. 3, No.2, pp 943-948 ISSN: 2278-238 Research Article
More informationAchieving Lipid Goals: 2008 Update. Laura Hansen, Pharm.D. Associate Professor, University of Colorado School of Pharmacy
Achieving Lipid Goals: 2008 Update Laura Hansen, Pharm.D. Associate Professor, University of Colorado School of Pharmacy Discuss relationship between lipid values and coronary events Evaluate clinical
More informationEzetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)
Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry
More informationANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD
ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed
More informationEstablished Risk Factors for Coronary Heart Disease (CHD)
Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland
More informationThe Pharmacists Role in Lipid Management
The Pharmacists Role in Lipid Management Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant Clinical Assistant Professor, Univ. of Maryland Learning Objectives 1. ENHANCE your understanding
More informationNCEP Report. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
NCEP Report Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Scott M. Grundy; James I. Cleeman; C. Noel Bairey Merz; H. Bryan Brewer,
More informationApplicability of Cholesterol-Lowering Primary Prevention Trials to a General Population
Applicability of Cholesterol-Lowering Primary Prevention Trials to a General Population The Framingham Heart Study ORIGINAL INVESTIGATION Donald M. Lloyd-Jones, MD; Christopher J. O Donnell, MD, MPH; Ralph
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More informationCoronary heart disease is the leading cause of death in
PHARMACOLOGY NOTES Ezetimibe (Zetia): a new type of lipid-lowering agent JIGNA PATEL, PHARMD CANDIDATE, VALERIE SHEEHAN, PHARMD, AND CHERYLE GURK-TURNER, RPH Coronary heart disease is the leading cause
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationJoshua Shepherd PA-C, MMS, MT (ASCP)
Joshua Shepherd PA-C, MMS, MT (ASCP) None What is Cholesterol? Why cholesterol is it important? Review the National Cholesterol Education Programs guidelines (NCEP-ATPIII) Discuss New guidelines from the
More informationTHE PAST DECADE HAS WITnessed
SPECIAL COMMUNICATION Clinical Goals and Performance Measures for Cholesterol Management in Secondary Prevention of Coronary Heart Disease Thomas H. Lee, MD James I. Cleeman, MD Scott M. Grundy, MD Clayton
More informationESC/EAS Guidelines for the Management of Dyslipidaemias
ESC/EAS Guidelines for the Management of Dyslipidaemias Professor Željko Reiner, MD, PhD, FRCP(Lond), FESC, FACC University Hospital Center Zagreb School of Medicine, University of Zagreb, Croatia Declaration
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationAcute Coronary Syndromes (ACS)
Sally A. Arif, Pharm.D., BCPS (AQ Cardiology) Assistant Professor of Pharmacy Practice Midwestern University, Chicago College of Pharmacy Cardiology Clinical Specialist, Rush University Medical Center
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationDiabetes, Diet and SMI: How can we make a difference?
Diabetes, Diet and SMI: How can we make a difference? Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Relative
More informationLIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Hyperlipidemias. Hyperlipoproteinemias. Hyperlipemia. Hypercholestrolemia. Direct relationship with acute pancreatitis and atherosclerosis Structure Lipoprotein Particles Types
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Overview
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Overview Ezetimibe for the treatment of primary (heterozygous familial and non-familial) hypercholesterolaemia The overview is written by members of
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationA N A C P S P E C I A L R E P O R T. Understanding and Managing Your. Triglycerides
A N A C P S P E C I A L R E P O R T Understanding and Managing Your Triglycerides What are Triglycerides? Triglycerides are one of several types of fat in your body, and the most common of them all. Along
More informationCoronary Artery Disease Clinical Practice Guidelines
Coronary Artery Disease Clinical Practice Guidelines Guidelines are systematically developed statements to assist patients and providers in choosing appropriate healthcare for specific clinical conditions.
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationHow much do we pay for a benefit? A Descriptive Cost Analysis of the Use of Statins. The Need for a National Cost- Effectiveness Analysis
Point of View How much do we pay for a benefit? A Descriptive Cost Analysis of the Use of Statins. The Need for a National Cost- Effectiveness Analysis José Luiz da Costa Vieira, Vera Lúcia Portal, Emílio
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationHDL-C. J Jpn Coll Angiol, 2008, 48: NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart
Online publication March 25, 2009 48 6 2007 2007 HDL-C LDL-C HDL-C J Jpn Coll Angiol, 2008, 48: 463 470 NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart 1987 NIPPON DATA80 Iso 10 MRFIT
More informationDYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
DYSLIPIDEMIA PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Know normal cholesterol levels Understand what the role
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW
ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP: #204. Ischemic Vascular Disease (IVD):
More informationSection Editor Mason W Freeman, MD
Official reprint from UpToDate www.uptodate.com 2015 UpToDate The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek
More informationConsiderations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction
Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Pamela B. Morris, MD, FACC, FAHA, FASCP, FNLA Chair, ACC Prevention of Cardiovascular Disease Council The Medical
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationThe updated guidelines from the National
BEYOND NCEP ATP III: LESSONS LEARNED AND FUTURE DIRECTIONS * Benjamin J. Ansell, MD, FACP ABSTRACT The National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines provide
More informationHyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi
Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationCLINICAL. Cholesterol Management of Patients With Diabetes in a Primary Care Practice Based Research Network
Cholesterol Management of Patients With Diabetes in a Primary Care Practice Based Research Network Dawn Fuke, PharmD; Jacquelyn Hunt, PharmD, BCPS; Joseph Siemienczuk, MD; Michael Estoup, PharmD; Michael
More informationLipid Management: Tools for Getting to the Goal
... PRESENTATIONS... Lipid Management: Tools for Getting to the Goal Based on a presentation by James M. McKenney, PharmD Presentation Summary The treatment of hypercholesterolemia in the United States
More informationNon-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017
Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017 Historical Basis for Fasting Lipids The initial classifications of hyperlipidemia proposed in 1967 were genetic and required
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationMetabolic Syndrome: Why Should We Look For It?
021-CardioCase 29/05/06 15:04 Page 21 Metabolic Syndrome: Why Should We Look For It? Dafna Rippel, MD, MHA and Andrew Ignaszewski, MD, FRCPC CardioCase presentation Andy s fatigue Andy, 47, comes to you
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More information4/24/15. AHA/ACC 2013 Guideline Key Points
Review of the ACC/AHA 2013 Guidelines Anita Ralstin, MS, CNS, CNP Next Step Health Consultant, LLC 1! Discuss the rationale for the change in lipid guidelines and how that affects the decision to implement
More informationEffects of Statins on Endothelial Function in Patients with Coronary Artery Disease
Effects of Statins on Endothelial Function in Patients with Coronary Artery Disease Iana I. Simova, MD; Stefan V. Denchev, PhD; Simeon I. Dimitrov, PhD Clinic of Cardiology, University Hospital Alexandrovska,
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationPreclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD
Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD 1 Preclinical? No symptoms No physical findings No diagnostic ECG findings No chest X-ray X findings No diagnostic events 2
More informationGuidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease Writing Committee Chair: Paul S. Jellinger,
More information